Thank you for submitting your manuscript for consideration by the EMBO Journal. Please let me apologise once again for the slight delay in getting back to you with a decision, but we have now received the third referee's report, and the comments of all three referees are appended below. As you will see, all three reviewers express interest in your work, but all raise significant concerns, primarily of a technical nature, that would need to be addressed by a major revision of your study. In particular, I would draw your attention to the comments of referee 2 regarding the need for appropriate controls throughout, and also to those of both referees 1 and 3 concerning the quality of the immunofluorescence images. (From an editorial viewpoint, I would say that -while electron microscopy would clearly be very valuable if you are able to undertake such analysis -I would not deem them essential; high-resolution confocal data should suffice.) It will also be important to address the concerns of referee 1 as to the possibility that your interaction mutants also affect other binding partners. Finally, all three referees argue that you need to distinguish more definitively between effects on internalisation and on degradation.
In the light of the referees' positive recommendations, I would therefore like to invite you to submit a revised version of the manuscript, addressing all the comments of all three reviewers (particularly, but not restricted to, those outlined above). I should add that it is EMBO Journal policy to allow only a single round of revision. Acceptance of your manuscript will thus depend on the completeness of your responses included in the next, final version of the manuscript. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS Referee #1 (Remarks to the Author):
Summary
This manuscript identifies a novel interaction between the GTPase dynamin 2 that promotes vesicle scission and the adaptor protein CIN85 that functions as a scaffold protein during endocytosis of various types of cell surface receptors, including growth factor receptors, such as the epidermal growth factor (EGF) receptor (EGFR). Interestingly, the dynamin 2-CIN85 interaction is induced after prolonged EGF stimulation (30-60 min), suggesting that the complex forms late in the endocytic pathway. The authors map the sites of interaction between the proteins, and create mutants that efficiently reduce their complex formation. Functional studies using these dynamin 2 and CIN85 mutants as well as RNA interference-mediated gene silencing and reconstitution experiments, show that interference with dynamin 2 and CIN85 functions leads to delayed EGF/EGFR degradation, accumulation of EGF in Rab7-positive late endosomes consisting of unusually elongated tubules and prolonged signaling downstream of the EGFR. This study provides a novel mechanism by which dynamin 2 and CIN85 act in the endocytic pathway and the authors suggest their cooperative action at late endosomes.
The data are interesting in the sense that they propose a new site of action of dynamin 2 in complex with CIN85 in late endosomal budding rather than at the plasma membrane, which is novel and of interest to the field. A major weakness is that the majority of the experiments are based on CIN85 and Dyn2 mutants that may interfere with further interactions than only the CIN85-Dyn2 interaction as discussed below.
Specific major comments
1.
A main conclusion in this manuscript is that "the interaction between CIN85 and dynamin 2 (Dyn2) is required for the efficient transport of EGF/EGFR from a late endosomal, Rab7-positive, compartment to lysosomes" (e.g. p.10). The weakness is however that this conclusion can mainly be based on the experiments using the Dyn2 mutant Dyn2-CBM (harboring point mutations of the 1st CIN85 interaction motif (PTPQRR -> ATAQRR) and a deletion of the 2nd CIN85 interaction motif (PAAPSR) (see point 2 below)). Importantly, similar motifs interact with the SH3 domains of the CIN85 homologue CMS/CD2AP (e.g. Kowanetz et al, 2003; Moncaliàn et al, 2006) . Consequently, loss of CMS/CD2AP interaction may also contribute to the effects observed. It would be important to test the interaction of Dyn2 and Dyn2-CBM with CMS/CD2AP and discuss the implications of this possible interaction/loss of interaction in the manuscript.
2.
Moreover, the CIN85AC W->Y mutant used in Figures 3, 4 , 7, S1 and S2 not only lacks the ability to interact with Dyn2, but also all other possible CIN85 effectors of the SH3 A and C domains, including numerous endocytic regulators (e.g. Havrylov et al., 2008; Dikic, 2002; Kowanetz et al., 2003 , Kowanetz et al., 2004 . The observed effects on EGF/EGFR degradation ( Figures 3 and 4) , late endosomal tubulation ( Figure 7 ) and prolonged EGFR signaling ( Figure S2 ) upon overexpression of this CIN85AC W->Y mutant are therefore very likely the total effect of disruption of various interactions along the endocytic pathway. All conclusions based on the CIN85AC W->Y mutant should therefore take this into account when drawn throughout the paper and a clear discussion about this should be included.
3.
The data in Figure 1 show co-localization between CIN85 and Dyn2 by immunofluorescence and in Figure 4B that Dyn2 and CIN85 can be found in a complex containing Rab7. However, to formally prove that the proteins indeed co-localize at late endosomes, immunoelectron microscopy studies of Dyn2 and CIN85 would be needed. Detailed co-localization analysis with Rab7 by confocal microscopy would also address this issue in more detail.
4.
The immunofluorescence studies in Figures 4A and 7A-C indicate that EGF accumulates in late endosomal compartments. The resolution at the immunofluorescence level is poor, and electron microscopy studies showing accumulation of EGF/EGFR in the elongated tubules arising upon Dyn-CBM (and/or CIN85AC W->Y) overexpression would be more convincing. 5.
Since the authors would like to propose a novel mechanism in which the Dyn2-CIN85 complex acts at late endosomes, it becomes even more important to exclude that any of the effects observed on EGF/EGFR degradation and signaling are due to defects in early EGF/EGFR internalization. On page 8, 1st paragraph, 1st line, the authors claim: "As the early stages of EGFR endocytosis were not impaired in the CIN85AC W-> Y mutant-expressing cells, ..." At this point they have not actually shown this, since Figures 3A, B and E do not include earlier time points than 30 minutes of EGF stimulation, a point at which the EGFR has already reached late endosomal compartments. The authors have indeed included one experiment in Figure S1 , where the CIN85AC W-> Y mutant does not seem to affect EGF internalization. The same experiment would also have to be performed with the Dyn2-CBM mutant. Moreover, complementary to the immunofluorescencebased approach in Figures 3 and S1 to measure EGF internalization, the authors should consider using more sensitive internalization assays based on 125I-EGF or biotinylation and measure EGFR levels at the cell surface also after earlier time points of EGF stimulation using the CIN85 and Dyn2 mutants. 6.
In the discussion the authors state (last sentence, p. 16): "Our data strongly suggest that CIN85 recruits Dyn2 to the late endosome where Dyn2 mediates a post-endosomal budding process that helps downregulate EGFR". There is no strong experimental evidence that CIN85 recruits Dyn2 to the late endosome. However, further experiments that would implicate this would help understanding the mechanism by which the complex acts at late endosomes. 7.
Appropriate statistical analyses of all quantification data (Figures 3, 7, 8, S1 , S2 and S3) should assay the siginificance of the differences observed.
Minor comments

8.
Whereas the data in Figure 2B and C show that SH3 domains A and C interact with Dyn2 using GST-CIN85 fusion proteins and lysates expressing Dyn2 or purified Dyn2 protein, the abolishment of the interaction has not formally been shown specifically for the CIN85AC W-> Y mutant, which is used in the functional assays in Figures 3, 4 , 7, S1 and S2. This could easily be proven in co-immunoprecipitation studies comparing the interaction of tagged wild-type CIN85 or a tagged CIN85AC W->Y mutant with Dyn2. 9.
In order to further substantiate their conclusions based on the Dyn2-CBM mutant, the authors should show or discuss whether the Dyn2-CBM mutant does not interfere with other reported functions of Dyn2. Alternatively, the main functional experiments (EGF/EGFR degradation, late endosomal tubulation and EGFR signaling) could be repeated with a Dyn2 mutant that has the minimum mutations to abolish CIN85/CMS/CD2AP interactions. Mutation of the arginine to alanine has been proven to abolish interactions with Px(P/A)xxR motifs (e.g. Kowanetz et al, 2003) . In the case of Dyn2, this would correspond to the following mutations: PTPQRR -> PTPQRA (CIN85 interaction motif 1) and PAAPSR -> PAAPSA (CIN85 interaction motif 2). 10.
GST-CIN85 levels should be included in Figures 2B and 2C . The same applies to GST-CIN85 and His-Dyn2 levels in Figure 1B . 11.
Quantification of the RhEGF intensity in the CIN85 and Dyn2 mutant-expressing compared to control cells would improve Figure 3E . 12. Figure 4 is based solely on the CIN85AC W->Y mutant. To strengthen the conclusion that EGF accumulates in Rab7-positive compartments due to a lack of the Dyn2-CIN85 interaction, this experiment should be performed with a Dyn2 mutant devoid of CIN85 interaction. Moroever, quantification of the amounts of RhEGF in the Rab7-positive endosomes at the different time points would improve Figure 4 . 13.
Please check the Results and Figure legends carefully for writing errors and completeness of information. For example, the final sentence of the Results section: "Taken together, these data suggest that the CIN85-Dyn2 complex is necessary for the formation if carriers emanating from the late endosomes resulting in a delay of EGFR degradation and the sustained downstream signaling". Should be changed to something in line with: "Taken together, these data suggest that the CIN85-Dyn2 complex is necessary for the formation if carriers emanating from the late endosomes and interference with this interaction results in a delay of EGFR degradation and the sustained downstream signaling". In the Figure 1D and E legends: "Two Dyn2-PRD-mutants were generated: P1 has a deletion of the C-terminal PAAPSR motif while the CBM bears the PAAPSR-deletion plus a PTPQRR -> ATAQRR double point mutation. (E) GST pulldown using GST-CIN85 and purified Dyn2-PRD-wt, P1 or CBM." 14.
Make sure to specify all abbreviations the first time used throughout the main text of the paper; e.g. proline-rich domain (PRD) and immunofluorescence (IF). 15.
Please correct and carefully check the headings of each section; Suggestion: "The SH3A and SH3C domains of CIN85 interact with the proline-rich domain of Dyn2" and "The CIN85-Dyn2 complex mediates vesiculation of late endosomes". 16. Figure S3 is referred to before Figure S2 in the main text. Figure S3 should thus be renamed to Figure S2 and vice versa. 17.
Indication of molecular weight standards are needed for all Western blots.
Referee #2 (Remarks to the Author):
In EMBO manuscript EMBOJ-2009-73488 by Schroeder et al. (A Dyn2-CIN85 complex mediates degradative traffic of the EGFR by regulation of late endosomal budding), the authors identify dynamin 2 and CIN85 as two interacting proteins. By identifying the interacting domains on each of the proteins, they are able to make mutants which disrupt the interactions between the two proteins.
In doing so, they identify a novel role for dynamin2 in mediating the late endocytic trafficking of the epidermal growth factor receptor (EGFR).
This manuscript is exciting in that it reveals a new function for dynamin 2. The order of experiments is logical and the manuscript is well written. However, several control experiments and experimental details would make this story much more compelling.
Major criticisms. Figure 3 -The data examining the rate of EGFR degradation are of poor quality. In fact, a comparison of panels A and C, do not even look like the same protein is being probed. Further, more appropriate controls for these studies are expression of wild type CIN85 (panel A) and wild type dynamin2 (panel C). Panel E does not provide a control.
Figure 4 -The appropriate control for this experiment is missing as well. In addition, a western blot probing for a protein that is expressed in the cell, but does not associate with rab7 vesicles would be compelling evidence the interaction was specific. Some of the most interesting data appear to be buried in the supplemental data. The fact that disrupting the CIN85/dyn2 interaction potentiates EGFR-mediated Erk, but not AKT, activity indicates this is an effector-specific, negative, regulator of EGFR signaling.
In addition, the most compelling evidence that a new role for dynamin2 in regulating comes from the knockdown and rescue of dynamin2. I would recommend this experiment be modified to demonstrate these two separate roles. Based on the work of others, I would predict that knockdown of dynamin2 would significantly attenuate the uptake of RhEGF. Further, I suspect expressing Dyn2-CBM in cell with attenuated levels of dynamin2 would restore RhEGF uptake, but not degradation.
Minor criticisms. Figure 1 and 2 -The authors demonstrate binding between dynamin2 and CIN85. In most experiments, they do include the whole cell lysate control, but do not indicate the relationship of this amount to the GST/HIS/IP isolated fraction.
In the introduction, the authors point out that the route of internalization of the EGF:EGFR complex (i.e. clathrin versus non-clathrin mediated) is dependent on the concentration of EGF. However, throughout the paper, they use concentration of EGF that favor non-clathrin mediated endocytosis. Perhaps, some rationale for using these concentrations should be given.
Referee #3 (Remarks to the Author):
While Dynamin is known as an essential protein involved in endocytosis, role in vesicle trafficking has not been investigated in details. This paper describes the identification of a novel complex formed by Cin85 and Dyn that is induced by EGFR stimulation and occurs late in the endocytic process..The authors attempted to characterize the complex biochemically and functionally. Disruption of this Dyn2-CIN85 interaction resulted in an accumulation of internalized EGFR at the Rab7 positive late endosome that becomes aberrantly elongated into distended tubules. While this is an interesting subject, it is yet hard to draw any definite conclusion from the data presented in the paper due to the following reasons.
While the experiments performed with overexpressed mutants are clear, results from KD experiments are not. In Fig 5. the delay in EGFR degradation seen in the Cin85 KD cells could be a direct consequence of a reduced internalization (which is only qualitatively measured with a single time point in the suppl). Reconstitution with Cin85 mutants in condition of Cin85 KD is mandatory. Since this is a crucial point, I believe that a different complementary approach should be undertaken in order to definitively prove a degradation defect. For instance, a quantitative assay using iodinated EGF should be employed, to follow the kinetic of internalization and degradation in control and KD cells.
The mechanism of action of the complex is not clear. The authors suggested that CIN85 recruits Dyn2 to the late endosome where Dyn2 mediates a post-endosomal budding process that helps downregulate EGFR. If the hypothesis is correct then how the Dynamin CBM mutant can work as a dominant negative?
The authors need to clarify this point by showing: -Dynamin localization at the level of the endosome at least by IF. This localization should disappear after Cin85 KD or CIN85 AC mutant expression.
-Rab7 pulldown in the absence of Cin85 (Fig 4b) . Dynamin should not be present in the absence of the recruiting interactor.
The entire set of IF experiments (Fig 4 and 6 ) performed with the Cin85 mutants are totally qualitative and not convincing. In addition they show separately co-localization with GFP-Rab7 for the AC mutant ( Fig. 4 ) and with GFP-Rab5 for the B mutant (Fig. 6 ). The authors need to repeat them in parallel with both markers and with a quantitation of the experiment.
Minor points
It is not clear if the interaction is constitutive or EGF regulated: co-localization and initial co-IP has been performed in growing condition (Fig 1a, b, c) . IF needs to be repeated with a time course exp. In addition it is not clear why the Cin85 signal is fairly visible in the lysate while it appears to be strong in IF. 
RESPONSE TO REVIEWER 1
This Reviewer thought that "the data are interesting in the sense that they propose a new site of action of dynamin 2 in complex with CIN85 in late endosomal budding rather than at the plasma membrane, which is novel and of interest to the field."
Reviewer's Comment 1: A main conclusion in this manuscript is that "the interaction between CIN85 and dynamin 2 (Dyn2) is required for the efficient transport of EGF/EGFR from a late endosomal, Rab7-positive, compartment to lysosomes" (e.g. p.10). The weakness is however that this conclusion can mainly be based on the experiments using the Dyn2 mutant Dyn2-CBM (harboring point mutations of the 1st CIN85 interaction motif (PTPQRR -> ATAQRR) and a deletion of the 2nd CIN85 interaction motif (PAAPSR) (see point 2 below)). Importantly, similar motifs interact with the SH3 domains of the CIN85 homologue CMS/CD2AP (e.g. Kowanetz et al, 2003; Moncali et al, 2006) . Consequently, loss of CMS/CD2AP interaction may also contribute to the effects observed. It would be important to test the interaction of Dyn2 and Dyn2-CBM with CMS/CD2AP and discuss the implications of this possible interaction/loss of interaction in the manuscript Reviewer's Comment 2: Moreover, the CIN85AC W->Y mutant used in Figures 3, 4 , 7, S1 and S2 not only lacks the ability to interact with Dyn2, but also all other possible CIN85 effectors of the SH3 A and C domains […] . The observed effects on EGF/EGFR degradation ( Figures 3 and 4) , late endosomal tubulation ( Figure 7 ) and prolonged EGFR signaling ( Figure S2 ) upon over-expression of this CIN85AC W->Y mutant are therefore very likely the total effect of disruption of various interactions along the endocytic pathway. All conclusions based on the CIN85AC W->Y mutant should therefore take this into account when drawn throughout the paper and a clear discussion about this should be included.
Authors' Response: We agree with the reviewer that other CIN85 interaction partners might also be affected by the CIN85AC W->Y mutant and we changed the discussion accordingly. Modifications in the manuscript are underlined.
Reviewer's Comment 3: The data in Figure 1 show co-localization between CIN85 and Dyn2 by immunofluorescence and in Figure 4B that Dyn2 and CIN85 can be found in a complex containing Rab7. However, to formally prove that the proteins indeed co-localize at late endosomes, immunoelectron microscopy studies of Dyn2 and CIN85 would be needed. Detailed co-localization analysis with Rab7 by confocal microscopy would also address this issue in more detail. Figure 7 is striking to us (now Figure 8) . To expand these studies further, we have included a similar set of stills in the modified Figure 9 (original Figure 8) Figure 9 and the corresponding changes in the text are underlined.
Reviewer's Comment 5: Since the authors would like to propose a novel mechanism in which the Dyn2-CIN85 complex acts at late endosomes, it becomes even more important to exclude that any of the effects observed on EGF/EGFR degradation and signaling are due to defects in early EGF/EGFR internalization. The authors have indeed included one experiment in Figure S1 , where the CIN85AC W-> Y mutant does not seem to affect EGF internalization. The same experiment would also have to be performed with the Dyn2-CBM mutant. Moreover, complementary to the immunofluorescence-based approach in Figures 3 and S1 to measure EGF internalization, the authors should consider using more sensitive internalization assays. Figure S3 (now supplemental Figure S6) Reviewer's Comment 7: Appropriate statistical analyses of all quantification data (Figures 3, 7 , 8, S1, S2 and S3) should assay the significance of the differences observed.
Authors' Response: We have included statistical analysis for all relevant figures.
Reviewer's Comment 8: Whereas the data in Figure 2B and C show that SH3 domains A and C interact with Dyn2 using GST-CIN85 fusion proteins and lysates expressing Dyn2 or purified Dyn2 protein, the abolishment of the interaction has not formally been shown specifically for the CIN85AC W-> Y mutant, which is used in the functional assays in Figures 3, 4 , 7, S1 and S2. This could easily be proven in co-immunoprecipitation studies comparing the interaction of tagged wildtype CIN85 or a tagged CIN85AC W->Y mutant with Dyn2. Figure  2B . Therefore we included new GST pulldown data using a fragment of CIN85wt (SH3ABC, comprising all SH3 domains) 
Authors' Response: We agree that the evidence for using the CIN85AC W->Y mutant in the original manuscript was mostly indirect based on the GST pulldown data presented in the original
or CIN85A(B)C W->Y (having a mutation in the SH3A and SH3C but not in the SH3B domain). Our data now formally demonstrate a markedly reduced interaction between the CIN85AC W->Y mutant and Dyn2 relative to the wt protein. We used these fragments because the full length protein degrades very easily and the SH3 domains are the only critical regions for the CIN85/Dyn2 interaction. The additional data are included as new panels C and D in the modified Figure 2.
Reviewer's Comment 9: In order to further substantiate their conclusions based on the Dyn2-CBM mutant, the authors should show or discuss whether the Dyn2-CBM mutant does not interfere with other reported functions of Dyn2. Figure 3 , now modified Figure 4 , and original supplemental Figure S3 , now modified supplemental Figure S6 ). Reviewer's Comment 10: GST-CIN85 levels should be included in Figures 2B and 2C . The same applies to GST-CIN85 and His-Dyn2 levels in Figure 1B .
Authors' Response: The most widely studied function of Dyn2 is in endocytosis and the scission of nascent vesicles from the plasma membrane. We stated in the original manuscript that this endocytic function of Dyn2 is not disrupted upon abolishment of the CIN85-Dyn2 complex by over-expression of binding mutants, and we also provided data to support that. For example, we examined early time points after EGF stimulation to determine the effects of the Dyn2wt and -CBM on early endocytic events (original
Authors' Response: Loading controls are now included in panels 1B, 1C and 2B in the modified Figures 1 and 2 as requested.
Reviewer's Comment 11: Quantification of the RhEGF intensity in the CIN85 and Dyn2 mutantexpressing compared to control cells would improve Figure 3E .
Authors' Response: We appreciate the reviewer's suggestion and added the requested IF and quantititation data. Due to requests by the other reviewers the original Figure 3 became too big, and therefore we split that Figure into two separate ones, having the IF data as Figure 3 and the biochemical data as Figure 4. We also adjusted the images for the CIN85AC W->Y expressing cells so that now all images are taken from pulse-chase assays. Quantitation of intracellular RhEGF shows a clear delay in degradation in the cells expressing either the CIN85AC W->Y or Dyn2-CBM mutants while the wt proteins had no effect compared to the MOCK treated cells. The new data are included as panels A, B and D into modified Figure 4, and corresponding changes in the text are underlined.
Reviewer's Comment 12: Figure is based solely on the CIN85AC W->Y mutant. To strengthen the conclusion that EGF accumulates in Rab7-positive compartments due to a lack of the Dyn2-CIN85 interaction, this experiment should be performed with a Dyn2 mutant devoid of CIN85 interaction. Moreover, quantification of the amounts of RhEGF in the Rab7-positive endosomes at the different time points would improve Figure 4 . Figure S4 and Reviewer's Comment 16: Figure S3 is referred to before Figure S2 in the main text. Figure S3 should thus be renamed to Figure S2 and vice versa.
Authors' Response: We agree that both of the suggested modifications improve the original Figure 4 (now Figure 5) and therefore we added the quantitation of the amount of RhEGF in the late endosome as new panel B in the modified Figure 5. The quantification was done using ImageJ software and it strongly supports the IF data showing that over-expression of the CIN85AC W->Y mutant retains RhEGF in the late endosome at time points when MOCK and CIN85wt expressing cells already show a decrease in co-localization. The CIN85B W->Y mutant, which retains RhEGF in the early endosome, does not reach a comparable level of co-localization, even at later time points. To use this mutant as an additional control was suggested by Reviewer # 2. We also performed RhEGF trafficking assays in HuH7 cells expressing either Dyn2wt or Dyn2-CBM and saw the same effect as for the CIN85AC W->Y mutant, namely retention of RhEGF in the late endosoma compartment. Because the additional modifications that were requested led to a substantial expansion of this figure, we decided to put the images for the RhEGF trafficking experiments using the Dyn2wt and CBM as new supplemental
Authors' Response: We changed the order of most of the figures in the revised manuscript due to addition of new data and made sure that the figures are referred to in the text in the appropriate order.
Reviewer's Comment 17: Indication of molecular weight standards are needed for all Western blots.
Authors' Response: We added molecular weight standards to all relevant figures as requested.
RESPONSE TO REVIEWER 2
The reviewer conveys enthusiasm for the study stating that "this manuscript is exciting in that it reveals a new function for dynamin 2. The order of experiments is logical and the manuscript is well written." Several control experiments and some more experimental details were requested.
Reviewer's Comment 1: The data examining the rate of EGFR degradation are of poor quality. Further, more appropriate controls for these studies are expression of wild type CIN85 (panel A) and wild type dynamin2 (panel C). Panel E does not provide a control.
Authors' Response: We improved this particular figure by taking the suggestions from all reviewers which led to a substantial expansion of the figure. Therefore we split the original figure 3 into modified Figure 3 (biochemistry) and modified Figure 4 (IF). The biochemical data now contain wt proteins as controls and show a clear difference between the wt and mutant proteins relative to the MOCK, supporting the findings that disruption of the CIN85-Dyn2 complex delays EGFR degradation. The new data are included in modified Figure 3. Corresponding changes in the text are underlined.
Reviewer's Comment 2: Figure 4 -The appropriate control for this experiment is missing as well. In addition, a western blot probing for a protein that is expressed in the cell, but does not associate with rab7 vesicles would be compelling evidence the interaction was specific. Figure 5 . We re-arranged the order of the figures in the revised manuscript to keep the flow of the story, therefore, the original figure 4 is now modified Figure 5 . Figure 7 in Reviewer's Comment 4: Figure 6B -The appropriate control is missing. Figure 6 and the corresponding IF data are presented in panel A in the new supplemental Figure S3 . The text was changed accordingly and changes in the text are underlined.
Authors' Response: We improved the IP in two ways: we used non-specific mouse IgG as control and also probed the blot with an antibody for E-Cadherin as a protein not related to Rab7-vesicles to prove specificity of the CIN85/Dyn2/Rab7 interaction as suggested by the reviewer. The new IP data confirm our previous observation that the interaction between CIN85/Dyn2 and Rab7 is specific and that Rab7 does not interact with E-Cadherin under the same conditions. Control IgG does not precipitate any of the examined proteins. The new IP data are included as new panel E in the modified
As a control for the IF data, we included CIN85wt and CIN85B W->Y into the trafficking assays and quantified the amount of co-localization between RhEGF and Rab7-endosomes for each protein. Including these controls shows that cells over-expressing CIN85wt behave like MOCK-treated cells, while over-expression of the CIN85 B W->Y mutant, which retains EGFR in the early endosomes, has a significant delay in trafficking EGFR to the late endosome. More details can be found in our answer to Reviewer #1's Comment #12. The new data are included as panels B and E in modified
Authors' Response: In the revised manuscript we included controls for the trafficking assays in the new Supplemental Figure S3 since a similar request was also raised by Reviewer #1 for the trafficking assays to the late endosome (see detailed answer to Reviewer #1's comment #12). As a control for Figure 6, we included CIN85wt and CIN85AC W->Y expressing cells in our studies. Further, we quantified the amount of RhEGF in the Rab5-positive early endosomes at each time point in the various CIN85 mutants and the wt compared to control cells, expressing Rab5 alone. These findings strongly support the IF data and demonstrate that the different CIN85 mutants have distinct trafficking defects. In this particular case, over-expression of CIN85 B W->Y causes a retention of RhEGF in the Rab5-positive early endosome while CIN85wt and CIN85 AC W->Y show no difference compared to the MOCK treated cells expressing Rab5 alone. The quantification is included as panel C in the modified
Reviewer's Comment 5: Some of the most interesting data appear to be buried in the supplemental data. The fact that disrupting the CIN85/Dyn2 interaction potentiates EGFR-mediated Erk, but not AKT, activity indicates this is an effector-specific, negative, regulator of EGFR signaling. Figure S1 and the corresponding changes in the text are underlined.
Authors' Response: We agree that this is a very interesting observation but the results are obviously a matter of debate among the reviewers. Since EGFR downstream signaling is not the focus of the paper, we decided to shorten that figure and now only show the pERK/ERK data to emphasize the differences in MAPK activation in the presence of the CIN85 and Dyn2 binding mutants compared to MOCK treated cells. This led to modified supplemental
Reviewer's Comment 6: In addition, the most compelling evidence that a new role for dynamin2 in regulating comes from the knockdown and rescue of dynamin2. I would recommend this experiment be modified to demonstrate these two separate roles. Based on the work of others, I would predict that knockdown of dynamin2 would significantly attenuate the uptake of RhEGF. Further, I suspect expressing Dyn2-CBM in cell with attenuated levels of dynamin2 would restore RhEGF uptake, but not degradation. Figure S6 (original supplemental Figure S3) Figure 9 in the revised manuscript. We hope that this clarifies the experimental approach we have taken for the Dyn2 knockdown/rescue assay. As mentioned above, the new data are included into modified supplelemntal Figure S6 and the corresponding changes in the text are underlined.
Authors' Response: We agree, we did not have the sh/-control (knockdown of Dyn2 only without reexpression of Dyn2 protein) in this figure and therefore, we included the knockdown data in panel B and in the quantitation panel C of the modified supplemental
Reviewer's Comment 7: Figure 1 and 2 -The authors demonstrate binding between dynamin2 and CIN85. In most experiments, they do include the whole cell lysate control, but do not indicate the relationship of this amount to the GST/HIS/IP isolated fraction.
Authors' Response: We thank the reviewer for this suggestion and have included the relative amount of the input in the figures as requested. Generally, we used 5-10% of the input as whole cell lysate control. Changes in the text are underlined.
Reviewer's Comment 8: In the introduction, the authors point out that the route of internalization of the EGF:EGFR complex (i.e. clathrin versus non-clathrin mediated) is dependent on the concentration of EGF. However, throughout the paper, they use concentration of EGF that favor non-clathrin mediated endocytosis. Perhaps, some rationale for using these concentrations should be given. 
RESPONSE TO REVIEWER 3
The Reviewer thought that "this is an interesting subject," but suggested several additional experiments to strengthen the conclusions.
Reviewer's Comment 1: While the experiments performed with over-expressed mutants are clear, results from KD experiments are not. In Fig 5. Soubeyran et al., Nature, 2002) . We used this particular construct in our study as well and also show an inhibitory effect on EGFR internalization (original supplemental Figure S2 , now supplemental Figure S1 ). However, the observed reduction in EGFR endocyosis might be a secondary effect due to sequestration of essential endocytic proteins such as Dyn2, for example. Our conclusions are also supported by a recent review by Havrylov and co-workers (Havrylov et al., Traffic, 2010) -Rab7 pulldown in the absence of Cin85 (Fig 4b) . Dynamin should not be present in the absence of the recruiting interactor. Reviewer's Comment 3: The entire set of IF experiments (Fig 4 and 6 ) performed with the Cin85 mutants are totally qualitative and not convincing. In addition they show separately co-localization with GFP-Rab7 for the AC mutant (Fig. 4) and with GFP-Rab5 for the B mutant (Fig. 6) . The authors need to repeat them in parallel with both markers and with a quantitation of the experiment. Reviewer's Comment 4: It is not clear if the interaction is constitutive or EGF regulated: colocalization and initial co-IP has been performed in growing condition (Fig 1a, b, Figure 1 show clearly that the interaction between CIN85 and Dyn2 is induced by EGF stimulation (Figure 1E and F modified at all by our publishers, and will be published as you provide it to us. At the moment, the changes made during revision are highlighted; this clearly needs to be fixed. I would also recommend that you change the orientation of some of the figures (from landscape to portrait) for easier reading.
Please could you therefore revise your manuscript as suggested by the referees and outlined above and resubmit a final version; I hope we should then be able to accept your study for publication without the need to consult referees again. Please don't hesitate to get in touch should you have any questions or comments.
Yours sincerely, Editor,
The authors have made an extensive revision. They have provided further experiments strengthening their conclusions about the role and site of action of the CIN85-Dyn2 complex and have shown that CIN85 recruits Dyn2 to late endosomes. In addition, they have included statistical analyses for all relevant experiments and several required controls and quantifications. The authors have thus addressed most of my concerns convincingly. However, there are some minor points remaining that I think would need to be addressed. As a whole, the manuscript has clearly been improved.
Minor points:
1. Even though the data suggest that the described effect on late endosomal budding upon overexpression of the CIN85 and Dyn2 mutants is due to a defect in the CIN85-Dyn2 interaction, I still feel that a clear statement that the CIN85ACW->Y mutant may affect other interactions than the binding to Dyn2 during EGFR degradation is missing (e.g. pages 10 and 16).
2. Some small corrections in the figures that I would recommend: Figure 3B , make text on x-axis fully visible; Figure 4B , include space: p < 0.0005; Figure 5B , adjust star denoting significance for CIN85B W->Y mutant in the graph; Figure 6C , centre the stars over the bars; Figure 7B , correct to RhEGF/lamp1; Figure 9E , reduce size of legend so that MOCK and siDyn2 are clearly apart; Figure  S1C and D, centre stars; Figure S2F , please check that the number for the surface EGFR (AV) in the EGF-stimulated Flag-Dyn2 CBM mutant lane is correct.
3. Page 13, second last sentence: Refers to Figure 9E only, and not also to Figure 9D .
4. Movies 8 and 9 are not referred to in the text and not described in the Supplementary Information. Moreover, the authors should carefully go through the text once again to correct small writing errors.
I appreciate the authors' considerable effort to address the concerns raised in the first round of reviewing. The manuscript is certainly improved and now provides more convincing evidences supporting an additional role for Dynamin2 (Dyn2) and CIN85 at the Rab7 endosomal station, besides their "canonical" role at the PM. In particular, the authors were able to nicely dissect the two distinct functions (early and late) of both proteins by in vivo reconstitution experiments, using WT and mutants that disr2upt CIN85-Dyn2 interaction. I believe that these crucial data (both CIN85 and Dyn2 reconstitution experiments) should be included in the main text. In agreement with the dual role proposed, the data presented in Figure S5 do show a delay in EGFR internalization in CIN85 KD (cells marked with a pound sign), besides the degradation defect. Yet, the authors seem to favor the idea (and biotinylation experiment seems to confirm) that CIN85 is not playing a major role in internalization. This important issue needs a definitive answer. As suggested in the first round of reviewing, I believe that a quantitative assay using iodinated EGF will be able to establish the kinetic of internalization in control and CIN85KD cells. In this way, the ambiguity still present in authors' conclusions would be definitely resolved.
-I suggest to move Figure 6B ,C to the supplementary information, while panel A can be included in Figure 2. What is clone 9? Why the authors used this cell line instead of HuH7 used along the entire manuscript? -In my opinion, the signaling data in Fig.S1 are still not convincing and should be removed.
Addtional Correspondence 09 June 2010
Thanks for the note and fast review of our manuscript. We are glad the Reviewers felt the story was much improved as we made a huge effort to do so!
We are fixing the minor things: more proofing, removing of the underlining of the text in the supplemental section and so on. The major issue remaining appears to be whether CIN85 is required for RME of the EGFR as mentioned by Rev #3. This Reviewer only had suggested performing iodination experiments to further pursue the internalization issue. You seem somewhat flexible as to how we address this provided we can add some additional quantitation. The iodination is difficult for us as it will take months to get the license and training, perform a new set of experiments, and cost us about $2,000. In our view the main issue is not the detection method (radioactivity versus biotinylation versus IF) but our ability to achieve a thorough knock down of CIN85.
If I could summarize what we have done so far toward quantitating the participation of CIN85 in the RME of EGF/R and what we might suggest. In the manuscript we show a role for CIN85 in EGF/R internalization in 4 different ways. First, we followed receptor-ligand uptake morphologically in cells expressing a CIN85 AC mutant construct (CIN85AC W->Y), or in cells depleted of CIN85. In both instances we observe no reduction or delay oftransport of Rhodamine-tagged EGF (RhEGF) to the early (Fig S3B) or late ( Fig.5A ) endosomes by fluorescence quantitation (Figs.5B and 6C ).
Second, in data not shown, which I attach below, we also quantitated receptor clearance from the surface by IF in non-permeabilized cells and see no inhibition in the mutant expressing cells (see below). We can mention this in the paper if useful. Third, we have performed EGFR surface biotinylation experiments in cells re-expressing the same CIN85AC W->Y mutant in the background of a CIN85 knockdown. We observed no reduction of uptake by the CIN85AC W->Y mutant (Fig. S5B ) and a 20% reduction of uptake in the siRNA treated cells but this was not statistically significant (Fig.7C ). I should mention that no one has reported a dependence of RME upon CIN85 to date, so our findings are not contradicting dogma. Fourth, RME studies in the background of a CIN85 knockdown have not been reported from what we can tell and the only CIN85 DN study was performed by Soubeyran et al (Soubeyran et al., Nature 2002) who did not express a true mutant but only over-expressed a fragment of CIN85 (the ABC SH3 domains, named !3SH3" in their publication) that is commonly referred to as dominantnegative CIN85. Using this mutant is quite different than a true point mutant, and led to only a ~20 % reduction in EGFR internalization (even less at earlier time points, similar to what we observed in our system; see Figure 3 d in the above mentioned Nature paper by Souybeyran et al);. In fact, if we use the same mutant, named SH3ABC in our manuscript, we also see a reduction (~ 40%) in EGF internalization measured by quantitation of RhEGF uptake ( Figure S2B and D) . Thus, all but one of the 4 approaches we have performed are quantified. I would like to suggest we pursue further biochemical quantitation per your request, of the biotinylation siRNA experiments. This is currently Fig. S5C (completion of a 3rd experiment is needed for standard error). The added experiments would provide a combined quantitative morphological/biochemical approach that would be very sound and it widely utilized in the field. Does this sound ok?
Additional Correspondence 09 June 2010
Many thanks for your message -your suggestions sound very reasonable and I am perfectly happy for you to proceed as you outline. I suspected that the iodination experiments might not be technically possible for you at this time, which was why I wanted to leave things somewhat flexible. It looks to me that your evidence is already pretty strong, and providing the additional quantitation of the biotinylation data should be enough to make the case. As for the figure you include in your previous message, in general we don't encourage citation of "data not shown" and so I suggest that you include this in the Supplementary Information and refer to it briefly in the text.
I do recognise the amount of work you've put into the paper already, and completely agree that it's a much improved story and will make a nice contribution to the journal. I hope these last few bits and pieces shouldn't prove too time-consuming and I look forward to receiving the final version soon! Yours sincerely,
Editor
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